During this World Glaucoma Week it is important to reiterate the clinical benefit of gaining IOP fluctuation insights outside of the clinic, a fundamental unmet need in clinical glaucoma.
According to Market Scope’s 2023 Annual Diagnostics Survey about at-home diagnostics and remote monitoring platforms, remote IOP monitoring was ranked #1 by 51% of respondents, making it the most likely to be integrated in practices as it becomes available.
Our iOP-Connect platform is the most viable upcoming technology to address this unmet need. Our first-in-class micro-battery-powered ultra-miniaturized intraocular implant enables autonomous logging of IOP 24/7 without disruption to patient lifestyle.
As a result, remote monitoring by the iOP-Connect system provides real-time visibility into the IOP-reducing effects of the therapy, which may lead to more effective personalized medicine, improved vision preservation, and patient quality of life.
Thanks Kristen Harmon Ingenito, MBA and Anthony (Tony) Ingenito for this valuable insight.
Comments